Palisade Bio PALI 深 沪
等待开盘 05-22 09:30:00 美东时间
2.01
+0.130
+6.91%
华盛通- 最 高2.06
- 今 开1.86
- 成交量 589.73万股
- 最 低 1.83
- 昨 收 1.88
- 总市值 34.89万
- 52周最高 2.855
- 市盈率 静 --
- 换手率 3.40%
- 52周最低 0.53
- 委 比 -48.84%
- 总股本 0.00亿
- 历史最高 18405.00
- 量 比 2.43
- 振 幅 12.23%
- 历史最低 0.53
- 每 手 1
- 风险率 0.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palisade Bio Q1 EPS $(0.05) Misses $(0.04) Estimate
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 89.36 percent increase over losses of $(0.47) per share from the
05-13 04:27
Palisade Bio Presents Additional Phase 1a/B Analyses Of PALI-2108, Including Delayed Ileocolonic Activation, High Tissue-To-Plasma Exposure, And Sustained Steady-State Concentrations Of Active Metabolite Above IC90, At Digestive Disease Week 2026
Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing intervalSteady-state pharmacokinetic findings provide mechanistic support for previously
05-05 20:36
美股牛股 | 史诗级轧空行情！安飞士本月累涨近400%；Velo3D飙涨超31%！成为米其林飞行员挑战赛官方技术提供商
史诗级轧空行情！安飞士本月累涨近400%；Velo3D飙涨超31%！成为米其林飞行员挑战赛官方技术提供商；POET涨超19%，正加速面向AI的光学转型>>
04-22 15:25
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7
Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.
04-10 00:38
Palisade Bio partners with Iterative Health to advance PALI-2108
Palisade Bio ( ($PALI) ) has provided an announcement. On March 30, 2026, Palis...
04-02 21:26
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
HC Wainwright & Co. Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
03-26 20:43
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
